Commercial OpportunityBrexafemme is an approved drug for vulvovaginal candidiasis, presenting a substantial commercial opportunity due to the unmet need.
Financial StabilityScynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.
Regulatory ApprovalThe FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Scynexis to resume the study.